AAminove
Back to library

Semaglutide

Human RCTApproved medicine

Also known as: Ozempic, Wegovy, Rybelsus

GLP-1 / incretinType 2 diabetesWeight management

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, chronic weight management. It is the best-evidenced peptide in this library, backed by large randomised trials.

Mechanism

Mimics glucagon-like peptide-1, enhancing glucose-dependent insulin secretion, slowing gastric emptying and reducing appetite via central pathways.

Evidence

Human RCTWhat does this mean?

Strong: multiple large phase 3 RCTs (SUSTAIN, STEP programmes) and regulatory approval.

Community-reported information

As a prescription medicine, dosing is set by the approved label and a clinician, typically titrated over weeks. This app does not restate a personalised schedule.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~7 days (once-weekly dosing)

Storage

Refrigerate 2–8 °C; in-use pens per label.

Commonly reported side effects

  • Nausea
  • Vomiting
  • Diarrhoea
  • Constipation
  • Injection-site reactions

Legal status by region

  • USFDA-approved prescription medicine.
  • GBMHRA-licensed; prescription only.
  • AUTGA-registered; prescription only (Schedule 4).

Legal status changes over time; verify locally before relying on this.

Citations